Bunnag C, Dhorranintra B, Jareoncharsri P
Department of Otolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Asian Pac J Allergy Immunol. 1988 Dec;6(2):116-20.
The efficacy and tolerability of a new intranasal glucocorticosteroid, budesonide, was evaluated in 28 Thai adult patients with perennial rhinitis. After one week pre-treatment observation period, the nasal spray was given as two puffs into each nostril twice daily (400 micrograms/day) for four weeks. The severity of all nasal symptoms decreased significantly after 1 week treatment reaching a minimal level after 2 weeks. The amounts of antihistamine tablets taken by the patients were also significantly reduced during the treatment with budesonide. Three patients reported adverse effects which were mild and easily tolerated. Morning plasma cortisol levels measured before and after four-week treatment in 15 patients revealed no significant changes. This study suggests that intranasal budesonide is an effective and well-tolerated treatment for perennial rhinitis.
在28名成年泰国常年性鼻炎患者中评估了一种新型鼻内糖皮质激素布地奈德的疗效和耐受性。经过为期一周的预处理观察期后，给予鼻喷雾剂，每侧鼻孔每日两次，每次两喷（400微克/天），持续四周。治疗1周后，所有鼻部症状的严重程度均显著降低，2周后达到最低水平。在布地奈德治疗期间，患者服用的抗组胺药片数量也显著减少。3名患者报告了不良反应，症状轻微且易于耐受。对15名患者在四周治疗前后测量的早晨血浆皮质醇水平显示无显著变化。这项研究表明，鼻内布地奈德是治疗常年性鼻炎的一种有效且耐受性良好的药物。
